Ingrid Gause‐Nilsson
AstraZeneca (Switzerland)(CH)AstraZeneca (Italy)(IT)AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, Diabetes Management and Research, Chronic Kidney Disease and Diabetes
Most-Cited Works
- → Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes(2018)6,145 cited
- → Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial(2019)663 cited
- → Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus(2019)555 cited
- → Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus(2020)438 cited
- → Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction(2019)327 cited
- → Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers(2016)186 cited